Alexion Pharmaceuticals, Inc.

Alexion Pharmaceuticals, Inc. Overview

Company Headquarters: Boston, US

Founded: 1992

Workforce: ~ 3082

Company Working: Alexion Pharmaceuticals, Inc. is a global biopharmaceutical company. The company researches and develops proprietary immunoregulatory compounds for the treatment of autoimmune and cardiovascular diseases. It develops C5 complement inhibitors and apogens which are two classes of potential therapeutic compounds designed to selectively target specific disease-causing segments of the immune system. The company has 4 growing, durable franchises and it serves more than 50 countries including major regions such as North America, Latin America, Europe, the Middle East, and Asia-Pacific.

Strategy

Alexion Pharmaceuticals, Inc. emphasizes serving patients and families affected by rare diseases through the discovery, development, and commercialization of life-changing therapies. The company focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on the core therapeutic areas of hematology, nephrology, neurology, metabolic disorders, and cardiology.

Company Snapshot

$3,549.5M

Revenue

3,082

Employees

1992

Founded

Boston, US

Headquarters

SWOT Analysis

Strengths

Strong global presence
Well developed distribution channel

Weaknesses

Limited success outside the core business

Opportunities

Limited success outside the core business

Threats

Limited success outside the core business
High competition from other players can affect the company’s market share
Risks related to Intellectual Property Rights (IPR)

Key Developments

Date	Approach	Development
December 2017	Approval	Alexion Pharmaceuticals, Inc. received the approval of the Ministry of Health, Labor and Welfare (MHLW) in Japan for Soliris (eculizumab) as a treatment for patients with generalized myasthenia gravis (gMG).
October 2017	Approval	Alexion Pharmaceuticals, Inc. received the approval of the US Food and Drug Administration (FDA) for Soliris (eculizumab) as a treatment for adult patients with generalized myasthenia gravis (gMG).
March 2017	Application	Alexion Pharmaceuticals, Inc. submitted an application to Japan's Ministry of Labor and Welfare (MHLW) to extend the indication for Soliris (eculizumab) as a potential treatment for patients with refractory generalized myasthenia gravis (gMG).
March 2017	Application	The US Food and Drug Administration (FDA) has accepted for review the Alexion Pharmaceuticals’ supplemental Biologics License Application (sBLA) to extend the indication for Soliris (eculizumab) as a potential treatment for patients with refractory generalized myasthenia gravis (gMG).

Product Offering

Alexion Pharmaceuticals, Inc.
- Medicines

Financial Performance

What our clients say

Trusted by forward-thinking businesses
for data-driven intelligence

Noah Malgeri

Co-Founder, Mojave Rail Fabrication Limited

This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.

Michael Robert

Manager, JavolVision

Thanks, I am so happy that we worked together. Maybe we still can work together in the future.

Joseph Aguayo

Sales Operations & Pricing Manager, Intel

Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.

Bong Lau

Sales Leader, Bamberg

We bought your "2025 report" in 2020. Everything is fine and very good.

Peter Groot Koerkamp

Account and Business Manager, EFS-Holland BV

Thanks for sending the report it gives us a good global view of the Betaïne market.

Younghwan Choi

Senior Retail Manager, LG Chem

We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.

Mark Irwin

Management Consultant, Level 21

I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.

Rob Kooiker

Group Product Manager HVAC & Fire Protection GMA, Rockwool

I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!

Jason Lee

R&D Director, Seojin

Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.

Akif Moroglu

Strategy & Business Development Director, Dogan Holding

We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.